

# CITATION REPORT

List of articles citing

Ulcerative colitis practice guidelines in adults:  
American College Of Gastroenterology, Practice  
Parameters Committee

DOI: 10.1038/ajg.2009.727

American Journal of Gastroenterology, 2010, 105,  
501-23; quiz 524.

**Source:** <https://exaly.com/paper-pdf/49364074/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1022	Oncologic outcome in patients with ulcerative colitis associated with dysplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. <b>2010</b> , 53, 1495-500		31
1021	Preparing the patient for immunosuppressive therapy. <b>2010</b> , 12, 502-6		5
1020	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. <b>2010</b> , 16 Suppl 1, S1-11		14
1019	Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence. <b>2010</b> , 1, 57-63		3
1018	Management of acute colitis and toxic megacolon. <b>2010</b> , 23, 274-84		27
1017	Pros and cons of medical management of ulcerative colitis. <b>2010</b> , 23, 227-38		5
1016	Tumor necrosis factor- $\alpha$ monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. <b>2010</b> , 39, 543-57		33
1015	How genetic variation affects patient response and outcome to therapy for psoriasis. <b>2010</b> , 6, 957-66		18
1014	Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. <b>2010</b> , 139, 1511-8		52
1013	Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. <b>2011</b> , 9, 483-489.e3		199
1012	Inflammatory bowel disease: perioperative pharmacological considerations. <b>2011</b> , 86, 748-57		33
1011	Conventional medical management of inflammatory bowel disease. <b>2011</b> , 140, 1827-1837.e2		164
1010	Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. <b>2011</b> , 5, 189-95		70
1009	Is the dose of thioguanine the key to better safety profile?. <b>2011</b> , 43, 96-7		
1008	Ulcerative colitis. <b>2011</b> , 365, 1713-25		785
1007	An evidence-based systematic review on medical therapies for inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106 Suppl 1, S2-25; quiz S26	0.7	205
1006	MMX $\square$ Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis. <b>2011</b> , 71, 221-35		15

1005	Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. <b>2011</b> , 124, e1-18	5
1004	Three initial diets for management of mild acute pancreatitis: a meta-analysis. <b>2011</b> , 17, 4235-41	15
1003	Current practice and perception of screening for medication adherence in inflammatory bowel disease. <b>2011</b> , 45, 878-82	27
1002	Risks and benefits of ileal pouchanal anastomosis for ulcerative colitis. <b>2011</b> , 8, 83-99	2
1001	Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients?. <b>2011</b> , 26, 683-7	18
1000	Review article: remission rates achievable by current therapies for inflammatory bowel disease. <b>2011</b> , 33, 870-9	111
999	Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. <b>2011</b> , 33, 996-1009	49
998	Review article: defining remission in ulcerative colitis. <b>2011</b> , 34, 113-24	145
997	Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. <b>2011</b> , 34, 747-56	25
996	Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. <b>2011</b> , 34, 1088-97	26
995	Existing dietary guidelines for Crohn's disease and ulcerative colitis. <b>2011</b> , 5, 411-25	71
994	A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. <b>2011</b> , 56, 513-22	35
993	Smoking and Barrett's esophagus in women who undergo upper endoscopy. <b>2011</b> , 56, 1707-17	11
992	Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. <b>2011</b> , 56, 3463-70	22
991	Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. <b>2011</b> , 46, 46-56	25
990	Development of quality measures for monitoring and improving care in gastroenterology. <b>2011</b> , 25, 387-95	2
989	Update on the management of ulcerative colitis. <b>2011</b> , 13, 475-85	14
988	New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. <b>2011</b> , 17, E8-9	8

987	High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1638-45	0.7	177
986	Update on the management of inflammatory bowel disease: specific role of adalimumab. <b>2011</b> , 4, 163-72		23
985	Acute severe ulcerative colitis: timing is everything. <b>2011</b> , 87, 215-22		11
984	Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 630-42	0.7	183
983	Lysozyme expression in microscopic colitis. <b>2011</b> , 64, 510-5		8
982	Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. <b>2011</b> , 14, 397-402		8
981	Readministration of calcineurin inhibitors for ulcerative colitis. <b>2012</b> , 46, 1315-21		5
980	Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice. <b>2012</b> , 2012, 271606		34
979	The effect of bifid triple viable on immune function of patients with ulcerative colitis. <b>2012</b> , 2012, 404752		14
978	Do we know how to use corticosteroids in acute severe ulcerative colitis?. <b>2012</b> , 3, 248-251		2
977	[Infection frequency in patients with chronic idiopathic ulcerative colitis]. <b>2012</b> , 77, 186-92		3
976	Higher apoptosis index and proliferation index in colonocytes of patients with ulcerative colitis in remission. <b>2012</b> , 84, 271-5		0
975	Ulcerative colitis. <b>2012</b> , 366, 861; author reply 862-3		1
974	Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1064-77	0.7	31
973	Gastrointestinal delivery of anti-inflammatory nanoparticles. <b>2012</b> , 509, 101-25		28
972	Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. <b>2012</b> , 15, 45-52		10
971	Mesalamine in the treatment and maintenance of remission of ulcerative colitis. <b>2012</b> , 5, 113-23		74
970	Trends in early outpatient drug therapy in pediatric inflammatory bowel disease in Finland: a nationwide register-based study in 1999-2009. <b>2012</b> , 2012, 462642		11

969	Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. <b>2012</b> , 5, 77-83		5
968	Chirurgie des maladies inflammatoires chroniques de l'intestin. <b>2012</b> , 7, 1-13		
967	The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease. <b>2012</b> , 24, 759-61		1
966	Infliximab versus ciclosporin in severe ulcerative colitis. <b>2012</b> , 380, 1887-8		6
965	Letter: real-life management of new onset ulcerative colitis and proctitis. <b>2012</b> , 36, 685-6; author reply 686		1
964	Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. <b>2012</b> , 36, 755-64		32
963	Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 167-76; author reply 177	0.7	106
962	Ulcerative colitis. <b>2012</b> , 380, 1606-19		1036
961	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <b>2012</b> , 380, 1909-15		394
960	[Current status of elective surgical treatment of ulcerative colitis. A systematic review]. <b>2012</b> , 90, 548-57		
959	Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. <b>2012</b> , 10, 513-9		42
958	Gastroenterologists and the triple aim: how to become accountable. <b>2012</b> , 22, 85-96		5
957	Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. <b>2012</b> , 41, 443-62		23
956	Biologic Therapy in Inflammatory Bowel Disease—Gastrointestinal Perspective. <b>2012</b> , 23, 81-88		
955	Health maintenance in the inflammatory bowel disease patient. <b>2012</b> , 41, 325-37		26
954	Strategies for the care of adults hospitalized for active ulcerative colitis. <b>2012</b> , 10, 1315-1325.e4		46
953	Using germline genomics to individualize pediatric cancer treatments. <b>2012</b> , 18, 2791-800		16
952	Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis. <b>2012</b> , 81, 379-85		27

951	Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. <b>2012</b> , 12, 108	47
950	Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. <b>2012</b> , 12, 132	32
949	Systems analysis of inflammatory bowel disease based on comprehensive gene information. <b>2012</b> , 13, 25	5
948	Diarrhea in chronic inflammatory bowel diseases. <b>2012</b> , 41, 651-75	23
947	Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. <b>2012</b> , 367, 616-24	576
946	Quality improvement in gastroenterology clinical practice. <b>2012</b> , 10, 1305-14	9
945	Once-daily budesonide MMX <sup>®</sup> extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. <b>2012</b> , 143, 1218-1226.e2	167
944	Ulcerative colitis practice guidelines in adults. <b>2012</b> , 36, 10-2	1
943	Ulcerative colitis practice guidelines in adults. <b>2012</b> , 36, 103-6	
942	Ulcerative colitis practice guidelines in adults. <b>2012</b> , 36, 107-9	4
941	Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. <b>2012</b> , 6, 470-5	59
940	Extended-release mesalamine granules for ulcerative colitis. <b>2012</b> , 46, 1529-36	11
939	Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. <b>2012</b> , 10, 1002-7; quiz e78	168
938	Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 179-94; author reply 195	0.7 117
937	Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. <b>2012</b> , 4, 41-50	10
936	Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. <b>2012</b> , 26, 795-8	15
935	[The effect of probiotics in ulcerative colitis]. <b>2012</b> , 60, 67-70	1
934	Inflammatory Bowel Disease. <b>2012</b> , 913-921	1

933	[Guidelines for the management of ulcerative colitis]. <b>2012</b> , 59, 118-40	25
932	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. <b>2012</b> , 18, 1057-63	38
931	Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. <b>2012</b> , 18, 1006-10	89
930	Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. <b>2012</b> , 18, 1026-33	26
929	Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. <b>2012</b> , 18, 2034-42	50
928	Cytomegalovirus infection and the gastrointestinal tract. <b>2012</b> , 14, 334-42	51
927	Management of acute, severe ulcerative colitis. <b>2012</b> , 13, 65-8	10
926	Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials. <b>2012</b> , 36, 126-34	9
925	Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. <b>2012</b> , 36, 248-56	19
924	Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. <b>2012</b> , 36, 569-74	44
923	Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. <b>2013</b> , 19, 301-8	3
922	Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. <b>2013</b> , 19, 221-9	16
921	Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. <b>2013</b> , 13, 23	36
920	Tumor necrosis factor inhibitors for inflammatory bowel disease. <b>2013</b> , 369, 754-62	225
919	My treatment approach to the management of ulcerative colitis. <b>2013</b> , 88, 841-53	2
918	Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel disease. <b>2013</b> , 77, 351-9	22
917	The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. <b>2013</b> , 145, 149-157.e2	157
916	Applicability of second-generation colon capsule endoscope to ulcerative colitis: a clinical feasibility study. <b>2013</b> , 28, 1174-9	47

915	Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement. <b>2013</b> , 23, 679-94	18
914	"One more time" 5-ASA retriial after a glucocorticosteroid induced remission in moderate to severe ulcerative colitis: a prospective community practice experience. <b>2013</b> , 7, 342-3	2
913	New therapeutic avenues in ulcerative colitis: thinking out of the box. <b>2013</b> , 62, 1642-52	48
912	Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. <b>2013</b> , 37, 953-62	117
911	State-of-the-art surgical approaches to the treatment of medically refractory ulcerative colitis. <b>2013</b> , 17, 2013-9	11
910	Metachronous, colitis-associated rectal cancer that developed after sporadic adenocarcinoma in an adenoma in a patient with longstanding Crohn's disease: a case report. <b>2013</b> , 11, 295	2
909	Management of dysplasia in patients with inflammatory bowel disease after liver transplantation. <b>2013</b> , 19, 671	
908	The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. <b>2013</b> , 38, 977-87	16
907	Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 444-9 <sup>0:7</sup>	62
906	Comparing guidelines for the treatment of inflammatory bowel disease. <b>2013</b> , 31, 360-2	
905	Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. <b>2013</b> , 38, 255-63	90
904	Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. <b>2013</b> , 58, 46-52	37
903	Cerebral sinus venous thrombosis in inflammatory bowel diseases. <b>2013</b> , 106, 401-13	49
902	Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article. <b>2013</b> , 48, 131-5	6
901	5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. <b>2013</b> , 7, 551-5	11
900	Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. <b>2013</b> , 7, 968-73	32
899	Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. <b>2013</b> , 11, 1281-7	18
898	The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study. <b>2013</b> , 7, e125-32	1



897	Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. <b>2013</b> , 7, e635-40	30
896	The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. <b>2013</b> , 36, 483.e1-483.e46	
895	[Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. <b>2013</b> , 36, e1-47	21
894	Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. <b>2013</b> , 36, 104-14	25
893	[Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine]. <b>2013</b> , 36, 7-10	2
892	A patient with ulcerative colitis and central serous chorioretinopathy--a therapeutic dilemma. <b>2013</b> , 7, e66-8	4
891	Patient awareness of extraintestinal manifestations of inflammatory bowel disease. <b>2013</b> , 7, e318-24	27
890	One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. <b>2013</b> , 37, 204-13	99
889	Traitement chirurgical de la rectocolite hémorragique. <b>2013</b> , 7, 27-34	
888	Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. <b>2013</b> , 27, 247-62	8
887	Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis. <b>2013</b> , 48, 104-10	29
886	Dysplastic lesions in inflammatory bowel disease: molecular pathogenesis to morphology. <b>2013</b> , 137, 338-50	50
885	Achievement of deep remission during scheduled maintenance therapy with TNF $\beta$ blocking agents in IBD. <b>2013</b> , 7, 730-5	79
884	Pharmacogenetics in clinical practice: how far have we come and where are we going?. <b>2013</b> , 14, 835-43	53
883	Automated identification of surveillance colonoscopy in inflammatory bowel disease using natural language processing. <b>2013</b> , 58, 936-41	26
882	Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. <b>2013</b> , 7, e684-91	55
881	Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. <b>2013</b> , 58, 2963-9	25
880	Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. <b>2013</b> , 57, 343-7	51

879	Novel treatment options for ulcerative colitis. <b>2013</b> , 3, 1057-1069	8
878	WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. <b>2013</b> ,	
877	Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease. <b>2013</b> , 1, 159-65	8
876	Surgical management of IBD--from an open to a laparoscopic approach. <b>2013</b> , 10, 297-306	34
875	The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. <b>2013</b> , 19, 2695-703	11
874	Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. <b>2013</b> , 45, 357-70	3
873	Dietary Interventions for Inflammatory Bowel Disease. <b>2013</b> , 39, 5-7	
872	What about the role of sulfasalazine?. <b>2013</b> , 185, 899	
871	Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids. <b>2013</b> , 19, 2644-51	6
870	Commentary: 5-ASA switches in IBD, adherence and flares--authors' reply. <b>2013</b> , 38, 1139	
869	Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study. <b>2013</b> , 38, 264-73	46
868	Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 90-8	0.7 107
867	Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. <b>2013</b> , 3, 1110	30
866	Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. <b>2013</b> , 19, 1913-20	73
865	Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. <b>2013</b> , 19, 1872-9	18
864	Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease. <b>2013</b> , 19, 669-71	9
863	Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. <b>2013</b> , 19, 2155-65	183
862	Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. <b>2013</b> , 19, 779-84	61

861	Thromboembolism in pediatric inflammatory bowel disease: the blood stops here. <b>2013</b> , 57, 265-6	1
860	Management of the elderly patients with inflammatory bowel disease: practical considerations. <b>2013</b> , 19, 2257-72	17
859	Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. <b>2013</b> , 19, 2182-9	11
858	Inflammatory bowel disease. 203-207	
857	Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy. <b>2014</b> , 76, 261-8	25
856	5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. <b>2014</b> , 9, e94208	49
855	Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease. <b>2014</b> , 28, 371-2	10
854	Current approaches to the management of new-onset ulcerative colitis. <b>2014</b> , 7, 111-32	30
853	New strategies for treatment of inflammatory bowel disease. <b>2014</b> , 1, 3	39
852	Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. <b>2014</b> , 20, 9872-81	230
851	Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. <b>2014</b> , 20, 9458-67	134
850	Ulcerative colitis-associated colorectal cancer. <b>2014</b> , 20, 16389-97	110
849	Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. <b>2014</b> , 7, 369-83	20
848	Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. <b>2014</b> , 28, 275-85	39
847	Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: a review. <b>2014</b> , 20, 3663-71	45
846	Golimumab for the treatment of ulcerative colitis. <b>2014</b> , 7, 53-9	19
845	Biological therapy for ulcerative colitis: an update. <b>2014</b> , 20, 13234-8	18
844	Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. <b>2014</b> , 20, 3173-9	42

843	Inflammatory bowel disease and thromboembolism. <b>2014</b> , 20, 13863-78	91
842	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. <b>2014</b> , 63, 442-50	136
841	Immunosuppressive agents. <b>2014</b> , 100-116	
840	Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?. <b>2014</b> , 10, 1563-5	1
839	Consider disease severity and response to corticosteroids when selecting agents to manage ulcerative colitis in children. <b>2014</b> , 30, 390-394	
838	Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice. <b>2014</b> , 12, 344	33
837	Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. <b>2014</b> , 49, 845-52	7
836	Xilei san ameliorates experimental colitis in rats by selectively degrading proinflammatory mediators and promoting mucosal repair. <b>2014</b> , 2014, 569587	10
835	Maintenance of Remission in Ulcerative Colitis. <b>2014</b> , 417-430	1
834	Colorectal cancer in inflammatory bowel disease: a shift in risk?. <b>2014</b> , 14, 847-56	5
833	Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. <b>2014</b> , 39, 1408-17	62
832	Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. <b>2014</b> , 40, 374-81	32
831	Review article: the psychosexual impact of inflammatory bowel disease in male patients. <b>2014</b> , 39, 1085-94	22
830	Adverse Drug Reactions. <b>2014</b> , 405-435	3
829	Glucocorticoid therapy for gastrointestinal diseases. <b>2014</b> , 13, 563-72	5
828	Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. <b>2014</b> , 48, 423-9	48
827	Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. <b>2014</b> , 20, 2046-55	6
826	Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. <b>2014</b> , 20, 631-6	37

825	Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. <b>2014</b> , 48, 351-5	8
824	A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. <b>2014</b> , 20, 1747-53	46
823	Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy. <b>2014</b> , 20, 1361-7	7
822	Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. <b>2014</b> , 20, 1714-21	72
821	Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis. <b>2014</b> , 20, 1399-406	5
820	Safety and activity of dersenazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. <b>2014</b> , 20, 2004-12	10
819	Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. <b>2014</b> , 259, 302-9	27
818	Probiotics, Prebiotics, and Antibiotics for Ulcerative Colitis. <b>2014</b> , 209-220	
817	Effect of MMX mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. <b>2014</b> , 8, 529-43	8
816	Treatment of Distal/Left-Sided Ulcerative Colitis. <b>2014</b> , 255-266	
815	Novel extended release budesonide formulation for treatment of ulcerative colitis. <b>2014</b> , 15, 131-7	1
814	Use of surveillance colonoscopy in medicare patients with inflammatory bowel disease prior to colorectal cancer diagnosis. <b>2014</b> , 90, 58-62	7
813	Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. <b>2014</b> , 126, 7-19	192
812	Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. <b>2014</b> , 12, 1324-9	61
811	Factors associated with readmissions and outcomes of patients hospitalized for inflammatory bowel disease. <b>2014</b> , 12, 1897-1904.e1	35
810	Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. <b>2014</b> , 59, 1001-11	34
809	Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. <b>2014</b> , 146, 835-848.e6	205
808	Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor- $\beta$ inhibitors in Crohn's disease. <b>2014</b> , 59, 554-63	10

807	Tissue IgG4-positive plasma cells in inflammatory bowel disease: a study of 88 treatment-naive biopsies of inflammatory bowel disease. <b>2014</b> , 27, 454-9	46
806	Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid. <b>2014</b> , 19, 960-7	5
805	Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. <b>2014</b> , 46, 330-4	10
804	Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk?. <b>2014</b> , 8, 166-71	18
803	Pediatric ulcerative colitis: a practical guide to management. <b>2014</b> , 16, 189-98	14
802	Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. <b>2014</b> , 112, 64-70	26
801	Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. <b>2014</b> , 39, 1095-103	45
800	The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. <b>2014</b> , 39, 940-8	9
799	Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. <b>2014</b> , 39, 1143-55	48
798	Vedolizumab: an $\alpha 4\beta 7$ integrin inhibitor for inflammatory bowel diseases. <b>2014</b> , 48, 1629-35	13
797	Clinical implications of ageing for the management of IBD. <b>2014</b> , 11, 128-38	33
796	The Hospitalized Adult with Severe Ulcerative Colitis. <b>2014</b> , 3, 531-541	
795	Demography and clinical course of ulcerative colitis in Arabs - a study based on the Montreal classification. <b>2014</b> , 49, 1432-40	6
794	Ulcerative colitis: epidemiology, diagnosis, and management. <b>2014</b> , 89, 1553-63	152
793	Implementation of image-enhanced endoscopy into solo and group practices for dysplasia detection in Crohn's disease and ulcerative colitis. <b>2014</b> , 24, 419-25	14
792	Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. <b>2014</b> , 46, 881-6	16
791	Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. <b>2014</b> , 147, 793-802	73
790	Bioequivalence for Drug Products Acting Locally Within Gastrointestinal Tract. <b>2014</b> , 297-334	2

789	Risks of Infection among the Older Inflammatory Bowel Disease Patients. <b>2014</b> , 12, 283-91	3
788	Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. <b>2014</b> , 15, 349-70	104
787	First case report of de novo ulcerative colitis developing after orthotopic liver transplantation successfully treated by granulocyte and monocyte apheresis. <b>2014</b> , 46, 2414-7	2
786	[Operative therapy of chronic inflammatory bowel diseases. Indications and importance]. <b>2014</b> , 55, 918-24	1
785	Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. <b>2014</b> , 70, 709-17	6
784	Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. <b>2014</b> , 29, 545-54	18
783	Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. <b>2014</b> , 29, 1159-70	11
782	Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. <b>2014</b> , 16, 407	8
781	Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. <b>2014</b> , 146, 110-118.e3	69
780	Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. <b>2014</b> , 146, 392-400.e3	593
779	Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. <b>2014</b> , 24, 469-81	15
778	Advanced endoscopic imaging techniques in Crohn's disease. <b>2014</b> , 8, 261-9	24
777	Venous thromboembolism risk in patients with inflammatory bowel disease: defining the benefits of pharmacologic prophylaxis. <b>2014</b> , 12, 1577	1
776	Quality bowel preparation for surveillance colonoscopy in patients with inflammatory bowel disease is a must. <b>2014</b> , 24, 379-92	15
775	The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. <b>2014</b> , 24, 353-65	17
774	Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid. <b>2014</b> , 468, 165-71	30
773	A tale of two diseases: the history of inflammatory bowel disease. <b>2014</b> , 8, 341-8	88
772	Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?. <b>2014</b> , 8, 80-4	2

771	Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. <b>2014</b> , 30, 67-78	10
770	Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. <b>2014</b> , 12, 1793-1800.e1	49
769	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. <b>2014</b> , 8, 1427-37	24
768	The Microbiota in Inflammatory Bowel Disease. <b>2014</b> , 187-203	
767	Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. <b>2015</b> , 21, 1204-13	19
766	Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study. <b>2015</b> , 21, 2576-82	12
765	Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice. <b>2015</b> , 38, 774-80	4
764	Cell therapy in experimental model of inflammatory bowel disease. <b>2015</b> , 35, 020-027	6
763	Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. <b>2015</b> , 60, 3408-17	11
762	Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study. <b>2015</b> , 16, 34	1
761	Etrolizumab for induction of remission in ulcerative colitis. <b>2015</b> , CD011661	1
760	Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. <b>2015</b> , 49, 582-8	34
759	Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis in Korea: The 1999-2005 Cohort. <b>2015</b> , 21, 1825-31	15
758	Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. <b>2015</b> , 21, 1719-36	25
757	Surgical and medical treatment in patients with acute severe ulcerative colitis. <b>2015</b> , 16, 558-67	17
756	Oral budesonide for induction of remission in ulcerative colitis. <b>2015</b> , CD007698	34
755	Ulcerative colitis outpatient management: development and evaluation of tools to support primary care practitioners. <b>2015</b> , 45, 1254-66	
754	Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <b>2015</b> , 21, 1976-81	10



753	Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days. <b>2015</b> , 21, 2130-6	19
752	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. <b>2015</b> , 21, 2562-9	24
751	Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. <b>2015</b> , 21, 1392-400	33
750	Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study. <b>2015</b> , 21, 163-70	3
749	[Prevention and treatment of thromboembolism in patients with inflammatory bowel disease]. <b>2015</b> , 65, 151-8	
748	Optimal management of steroid-dependent ulcerative colitis. <b>2015</b> , 8, 293-302	12
747	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The patient perspective. <b>2015</b> , 29, 294-6	6
746	Hereditary Angioedema and Gastrointestinal Complications: An Extensive Review of the Literature. <b>2015</b> , 2015, 925861	15
745	Altered chemokine signalling in endothelial progenitor cells from acute ulcerative colitis patients. <b>2015</b> , 2015, 843980	3
744	An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease. <b>2015</b> , 21, 1064-76	8
743	Sexual dysfunction in inflammatory bowel disease: "don't ask, don't tell" doesn't work. <b>2015</b> , 21, 948-50	5
742	Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. <b>2015</b> , 41, 603-12	25
741	A content-based image retrieval method for optical colonoscopy images based on image recognition techniques. <b>2015</b> ,	1
740	Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly. <b>2015</b> , 13, 275-86	15
739	Systematic review of health-related quality of life measures for inflammatory bowel disease. <b>2015</b> , 9, 284-92	42
738	Vedolizumab: an $\alpha 4\beta 7$ integrin antagonist for ulcerative colitis and Crohn's disease. <b>2015</b> , 6, 224-33	28
737	Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. <b>2015</b> , 72, 1271-8	6
736	Development of Advanced Imaging Criteria for the Endoscopic Identification of Inflammatory Polyps. <b>2015</b> , 6, e128	5

735	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. <b>2015</b> , 14, 1915-34	3
734	The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story. <b>2015</b> , 148, 877-80	1
733	Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?. <b>2015</b> , 13, 336-8	27
732	Predicting outcomes in acute severe ulcerative colitis. <b>2015</b> , 9, 405-15	8
731	Gastrointestinal disorders. <b>2015</b> , 1-16	
730	Prevalence of chronic narcotic use among children with inflammatory bowel disease. <b>2015</b> , 13, 310-315.e2	19
729	Drug Management in the Elderly IBD Patient. <b>2015</b> , 13, 90-104	9
728	Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?. <b>2015</b> , 13, 130-42	7
727	Quality indicators for colonoscopy. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 72-90	0.7 266
726	Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. <b>2015</b> , 148, 740-750.e2	73
725	Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. <b>2015</b> , 41, 409-18	52
724	Primary linitis plastica of the entire colon in a background of ulcerative colitis: a case report. <b>2015</b> , 13, 16	1
723	Minimal invasive surgery: NOSE and NOTES in ulcerative colitis. <b>2015</b> , 29, 3313-8	22
722	CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. <b>2015</b> , 34, 13-18	35
721	Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. <b>2015</b> , 41, 821-34	47
720	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <b>2015</b> , 148, 1035-1058.e3	251
719	What Is the Best Therapy for My Moderate to Severe Ulcerative Colitis? State-of-the-Art Therapy for Moderate to Severe Ulcerative Colitis. <b>2015</b> , 79-89	
718	If variety is the spice of life, we need to rethink our recipe: variation in inflammatory bowel disease practice among tertiary centers. <b>2015</b> , 13, 1201-3	1

717	The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. <b>2015</b> , 91, 239-47	110
716	Positioning Therapy for Ulcerative Colitis. <b>2015</b> , 17, 29	12
715	Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels. <b>2015</b> , 15, 211-5	8
714	What is the Best Possible Therapy for My Mild to Moderate Ulcerative Colitis? State-of-the-Art Therapy for Mild to Moderate Ulcerative Colitis. <b>2015</b> , 73-78	
713	Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. <b>2015</b> , 9, 497-505	13
712	Chromocolonoscopy. <b>2015</b> , 25, 243-60	13
711	TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. <b>2015</b> , 42, 132-44	44
710	Inflammatory bowel disease and the elderly: a review. <b>2015</b> , 9, 507-15	82
709	The role of endoscopy in inflammatory bowel disease. <b>2015</b> , 81, 1101-21.e1-13	216
708	Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods. <b>2015</b> , 75, 355-61	8
707	5-Aminosalicylic acid, a specific drug for ulcerative colitis. <b>2015</b> , 50, 933-41	38
706	A Thermo-Sensitive Delivery Platform for Topical Administration of Inflammatory Bowel Disease Therapies. <b>2015</b> , 149, 52-55.e2	16
705	Budesonide MMX(□): a review of its use in patients with mild to moderate ulcerative colitis. <b>2015</b> , 75, 879-86	9
704	Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels. <b>2015</b> , 32, 477-84	22
703	Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. <b>2015</b> , 21, 564-9	9
702	Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. <b>2015</b> , 60, 2251-63	35
701	Frequency and Appropriateness of Fasting Orders in the Hospital. <b>2015</b> , 90, 1225-32	20
700	Ulcerative Colitis: Update on Medical Management. <b>2015</b> , 17, 44	24

699	Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?. <b>2015</b> , 6, 617-639	208
698	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management. <b>2015</b> , 30, 1595-602	2
697	Indications and Options for Surgery in Ulcerative Colitis. <b>2015</b> , 95, 1211-32, vi	23
696	Cerebral venous thrombosis in inflammatory bowel disease. <b>2015</b> , 16, 104-8	11
695	Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. <b>2015</b> , 41, 99-107	8
694	An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. <b>2015</b> , 7, 300ra128	196
693	Biologic agents for IBD: practical insights. <b>2015</b> , 12, 537-45	196
692	Primary Care of the Patient with Inflammatory Bowel Disease. <b>2015</b> , 99, 969-87	5
691	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. <b>2015</b> , 9, 738-46	23
690	Acute Infectious and Inflammatory Enterocolitides. <b>2015</b> , 53, 1255-71	6
689	Knowledge and predictors of dysplasia surveillance performance in inflammatory bowel diseases in Australia. <b>2015</b> , 82, 708-714.e4	9
688	Conventional drug therapy for inflammatory bowel disease. <b>2015</b> , 50, 90-112	44
687	Quality indicators for colonoscopy. <b>2015</b> , 81, 31-53	614
686	Managing acute severe ulcerative colitis in the hospitalised setting. <b>2015</b> , 6, 241-245	3
685	The diagnosis of inflammatory bowel disease is often unsupported in clinical practice. <b>2015</b> , 47, 20-3	9
684	Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. <b>2015</b> , 165, 270-82	87
683	Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. <b>2015</b> , 50, 255-63	33
682	MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. <b>2016</b> , 29, 201-205	10

681	Diet and nutritional factors in inflammatory bowel diseases. <b>2016</b> , 22, 895-905	118
680	Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. <b>2016</b> , 7, 5-20	34
679	Role of antibiotics for treatment of inflammatory bowel disease. <b>2016</b> , 22, 1078-87	122
678	Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. <b>2016</b> , 9, 125-30	17
677	Elderly patients and inflammatory bowel disease. <b>2016</b> , 7, 51-65	36
676	Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. <b>2016</b> , 2016, 6928710	3
675	Hydroalcoholic Extract from Inflorescences of (Compositae) Ameliorates Dextran Sulphate Sodium-Induced Colitis in Mice by Attenuation in the Production of Inflammatory Cytokines and Oxidative Mediators. <b>2016</b> , 2016, 3475356	12
674	Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response. <b>2016</b> , 2016, 4312538	8
673	A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. <b>2016</b> , 14, 248-57	5
672	An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. <b>2016</b> , 12, 1097-1109	11
671	Fulminant ulcerative colitis complicated by treatment-refractory bacteremia. <b>2016</b> , 29, 407-408	1
670	Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. <b>2016</b> , 11, e0160500	8
669	The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West?. <b>2016</b> , 1, 78-84	2
668	Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. <b>2016</b> , 10, 593-607	6
667	Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. <b>2016</b> , 22, 2030-45	45
666	Inflammatory bowel disease surgery in the biologic era. <b>2016</b> , 8, 363-70	30
665	How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients. <b>2016</b> , 22, 1219-30	15
664	NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor- $\alpha$ -Inhibitors. <b>2016</b> , 63, 130-55	17

663	Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. <b>2016</b> , 22, 631-7	19
662	Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. <b>2016</b> , 22, 1435-41	20
661	Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. <b>2016</b> , 36, 472-81	6
660	Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. <b>2016</b> , 50, 318-25	15
659	Management of Inflammatory Bowel Disease in the Elderly. <b>2016</b> , 14, 285-304	19
658	The use of optical imaging techniques in the gastrointestinal tract. <b>2016</b> , 7, 207-215	8
657	Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. <b>2016</b> , 3, 4-7	2
656	Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. <b>2016</b> , 10, 1310-1315	12
655	French national consensus clinical guidelines for the management of ulcerative colitis. <b>2016</b> , 48, 726-33	14
654	Challenges in detection and real-time diagnosis of dysplasia in Crohn's colitis: the search still continues. <b>2016</b> , 83, 972-4	1
653	Cancer and inflammatory bowel disease in the elderly. <b>2016</b> , 48, 1105-11	23
652	Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. <b>2016</b> , 9, 548-59	13
651	Budesonide for the treatment of ulcerative colitis. <b>2016</b> , 17, 1549-59	23
650	Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. <b>2016</b> , 10, 1294-1302	45
649	Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences. <b>2016</b> , 1, 15-23	31
648	Crohn's Disease: Surgical Management. <b>2016</b> , 843-868	1
647	Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. <b>2016</b> , 61, 1003-12	16
646	Population-based screening for cancer: hope and hype. <b>2016</b> , 13, 550-65	64

645	Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?. <b>2016</b> , 61, 2205-2216	6
644	Cytomegalovirus-Related Hospitalization Is Associated With Adverse Outcomes and Increased Health-Care Resource Utilization in Inflammatory Bowel Disease. <b>2016</b> , 7, e150	14
643	Management of Acute Severe Colitis in Children With Ulcerative Colitis in the Biologics Era. <b>2016</b> , 137,	12
642	IBD Diagnosis and Evaluation. <b>2016</b> , 771-786	
641	Medical Management of Chronic Ulcerative Colitis. <b>2016</b> , 787-806	
640	Lower Abdominal Pain. <b>2016</b> , 34, 229-49	4
639	Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. <b>2016</b> , 12, 833-42	2
638	Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. <b>2016</b> , 10, 1005-10	4
637	Endoscopic evaluation for colon cancer and dysplasia in patients with inflammatory bowel disease. <b>2016</b> , 18, 145-151	1
636	Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. <b>2016</b> , 9, 887-894	92
635	Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests. <b>2016</b> , 138, 943-955	16
634	Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. <b>2016</b> , 44, 1018-1029	30
633	Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. <b>2017</b> , 11, 335-341	14
632	Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. <b>2016</b> , 12, 829-834	5
631	Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. <b>2016</b> , 72, 1319-1325	5
630	IBD: A timely diagnosis of primary sclerosing cholangitis in IBD. <b>2016</b> , 13, 565-6	1
629	Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. <b>2016</b> , 44, 482-94	32
628	Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. <b>2016</b> , 43 Suppl 1, 27-36	39

627	Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. <b>2016</b> , 28, 260-5	16
626	Acute severe ulcerative colitis: from pathophysiology to clinical management. <b>2016</b> , 13, 654-664	80
625	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. <b>2016</b> , 44, 157-69	37
624	Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey. <b>2016</b> , 33, 1715-1727	7
623	Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption. <b>2016</b> , 14, 1173-9	26
622	A Case of Thiopurine-Induced Acute Myocarditis in a Patient with Ulcerative Colitis. <b>2016</b> , 61, 3633-3634	2
621	Prediction of low bone mineral density in patients with inflammatory bowel diseases. <b>2016</b> , 4, 669-676	18
620	Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. <b>2016</b> , 16, 255	43
619	European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. <b>2017</b> , 11, 263-273	59
618	What Is the Best Approach to Avoid Colorectal Cancer Risk in Inflammatory Bowel Disease?. <b>2016</b> , 12, 345-351	
617	Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. <b>2016</b> , 22, 1881-6	7
616	The Role of Laboratory Tests in Crohn's Disease. <b>2016</b> , 9, 51-62	14
615	Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. <b>2016</b> , 62, 372-7	9
614	Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. <b>2016</b> , 68, 816-26	88
613	Electronic Imaging in Colonoscopy: Clinical Applications and Future Prospects. <b>2016</b> , 14, 140-51	4
612	Vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a guide to its use. <b>2016</b> , 32, 265-275	1
611	Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity. <b>2016</b> , 3, 88-94	5
610	Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. <b>2016</b> , 61, 221-9	3



609	Maintenance therapy options for ulcerative colitis. <b>2016</b> , 17, 1339-49	13
608	Immunohistochemical expression of proinflammatory enzyme COX-2 and p53 in ulcerative colitis and its associated dysplasia and colorectal carcinoma. <b>2016</b> , 4, 195-202	2
607	Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. <b>2016</b> , 22, 1744-54	37
606	Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. <b>2016</b> , 18, O97-O102	10
605	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <b>2016</b> , 48, 360-70	29
604	Colorectal Cancer Screening in Inflammatory Bowel Disease. <b>2016</b> , 61, 980-9	25
603	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <b>2016</b> , 10, 149-58	57
602	Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program. <b>2016</b> , 15, 204-12	28
601	Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. <b>2016</b> , 10, 925-33	20
600	Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. <b>2016</b> , 128, 273-81	8
599	Biosimilars: Rationale and current regulatory landscape. <b>2016</b> , 45, S1-10	36
598	Antimicrobial effect of salicylamide derivatives against intestinal sulfate-reducing bacteria. <b>2016</b> , 14, 125-130	32
597	Colonoscopy Surveillance and Management of Dysplasia in Inflammatory Bowel Disease. <b>2016</b> , 14, 103-14	5
596	Evaluation and Detection of Dysplasia in IBD: the Role of Chromoendoscopy and Enhanced Imaging Techniques. <b>2016</b> , 14, 73-82	7
595	Preventive effect of carob (Ceratonia siliqua L.) in dextran sulfate sodium-induced ulcerative colitis in rat. <b>2016</b> , 6, 19992-20000	8
594	JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. <b>2016</b> , 310, G155-62	100
593	The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. <b>2016</b> , 61, 589-96	11
592	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <b>2016</b> , 150, 734-757.e1	261

591	Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. <b>2016</b> , 61, 358-70	26
590	Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients. <b>2016</b> , 22, 811-816	9
589	Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. <b>2016</b> , 1008, 1-10	5
588	The management of autoimmunity in patients with cholestatic liver diseases. <b>2016</b> , 10, 73-91	8
587	Laboratory Tests in Crohn's Disease. <b>2016</b> , 15-30	
586	Cancer Surveillance of Patients with Long-Standing Inflammatory Bowel Disease. <b>2016</b> , 61-83	
585	Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. <b>2016</b> , 150, 389-95.e3	30
584	Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <b>2016</b> , 34, 245-57	14
583	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. <b>2016</b> , 83, 1005-12	32
582	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <b>2016</b> , 14, 348-354.e17	17
581	Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration - experience from a pediatric tertiary care facility. <b>2017</b> , 24, 74-80	30
580	Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. <b>2017</b> , 52, 185-193	11
579	Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease. <b>2017</b> , 23, 501-510	31
578	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <b>2017</b> , 49, 338-358	34
577	Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. <b>2017</b> , 10, 391-400	4
576	Surgery of acute severe ulcerative colitis. Subtotal colectomy: when and how to do it?. <b>2017</b> , 49, 108-112	2
575	Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. <b>2017</b> , 20, 409-422	6
574	Chemoprevention of colorectal cancer in inflammatory bowel disease. <b>2017</b> , 17, 247-255	10

573	ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 241-258	0.7	241
572	Surveillance for dysplasia in patients with ulcerative colitis: Discrepancy between guidelines and practice. <b>2017</b> , 29, 584-593		12
571	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. <b>2017</b> , 45, 617-630		50
570	Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases. <b>2017</b> , 152, 1337-1344.e3		24
569	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <b>2017</b> , 82, 46-84		2
568	Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. <b>2017</b> , 239, 115-146		41
567	Neurological Complications of Gastrointestinal Disease. <b>2017</b> , 24, 43-53		3
566	The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. <b>2017</b> , 18, 23		101
565	Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease. <b>2017</b> , 52, 833-839		5
564	Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. <b>2017</b> , 129, 538-553		15
563	Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. <b>2017</b> , 23, 1057-1064		29
562	Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. <b>2017</b> , 23, 882-893		44
561	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <b>2017</b> , 11, 649-670		837
560	Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. <b>2017</b> , 19, 1108-1116		12
559	Emerging treatments for ulcerative colitis: a systematic review. <b>2017</b> , 52, 923-931		9
558	Optimizing pharmacologic management of inflammatory bowel disease. <b>2017</b> , 10, 595-607		21
557	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <b>2017</b> , 376, 1723-1736		771
556	Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. <b>2017</b> , 7, 46693		6

555	Incidence of Cancer and Screening in Inflammatory Bowel Disease. <b>2017</b> , 639-652	
554	Ulcerative colitis. <b>2017</b> , 389, 1756-1770	1146
553	Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. <b>2017</b> , 15, 1218-1225.e7	20
552	New treatment strategies for ulcerative colitis. <b>2017</b> , 13, 963-973	25
551	Diagnosis and management of inflammatory bowel disease in children. <b>2017</b> , 357, j2083	49
550	Dysplasia and Cancer in Inflammatory Bowel Disease. <b>2017</b> , 97, 627-639	17
549	Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply. <b>2017</b> , 45, 1554-1555	
548	Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. <b>2017</b> , 46, 292-302	20
547	Fecal microbiota transplantation for gastrointestinal disorders. <b>2017</b> , 33, 8-13	22
546	Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study. <b>2017</b> , 11, 970-974	8
545	Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. <b>2017</b> , 11, 785-791	40
544	Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. <b>2017</b> , 23, 494-501	16
543	Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis. <b>2017</b> , 17, 28	11
542	Ulcerative Colitis Treatment Patterns and Cost of Care. <b>2017</b> , 20, 752-761	22
541	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. <b>2017</b> , 23, 570-577	58
540	Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. <b>2017</b> , 11, 767-768	2
539	A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis. <b>2017</b> , 23, 991-997	7
538	Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. <b>2017</b> , 12, 12-22	5

537	Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. <b>2017</b> , 17, 28	10
536	Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. <b>2017</b> , 15, 850-856	18
535	Infliximab for ipilimumab-induced colitis: A series of 13 patients. <b>2017</b> , 13, e284-e290	21
534	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <b>2017</b> , 82, 46-84	15
533	Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. <b>2017</b> , 62, 2982-2990	21
532	Optimizing the quality of endoscopy in inflammatory bowel disease: focus on surveillance and management of colorectal dysplasia using interactive image- and video-based teaching. <b>2017</b> , 86, 1107-1117.e14	14
531	MMX technology and its applications in gastrointestinal diseases. <b>2017</b> , 10, 545-552	16
530	Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. <b>2017</b> , 23, 1689-1701	14
529	IBD HINTS for Preventive Care. <b>2017</b> , 23, E42	
528	The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. <b>2017</b> , 49, 1092-1097	7
527	Cost of Illness in Inflammatory Bowel Disease. <b>2017</b> , 62, 2318-2326	15
526	Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. <b>2017</b> , 40 Suppl 1S, S1-S14	
525	Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. <b>2017</b> , 34, 859-868	23
524	An Update on Inflammatory Bowel Disease. <b>2017</b> , 44, 673-692	193
523	Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. <b>2017</b> , 96, e6788	18
522	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <b>2017</b> , 46, 389-400	206
521	Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. <b>2017</b> , 18, 8	19
520	Tricks of the Trade: Treating Your Patient with Moderate-to-Severe IBD. <b>2017</b> , 147-182	

519	It's Quality, Not Quantity, That Matters <b>2017</b> , 333-343	
518	Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis. <b>2017</b> , 32, 558-566	8
517	Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. <b>2017</b> , 32, 769-777	20
516	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. <b>2017</b> , 30, 191-231	41
515	Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. <b>2017</b> , 48, 247-257	82
514	Low Rate of Dysplasia Detection in Mucosa Surrounding Dysplastic Lesions in Patients Undergoing Surveillance for Inflammatory Bowel Diseases. <b>2017</b> , 15, 222-228.e2	25
513	Specifics and Pitfalls in Diagnosis of Inflammatory Bowel Diseases. <b>2017</b> , 347-354	
512	An Electronic Alert System Is Associated With a Significant Increase in Pharmacologic Venous Thromboembolism Prophylaxis Rates Among Hospitalized Inflammatory Bowel Disease Patients. <b>2017</b> , 39, 307-314	7
511	Pectin-silica gels as matrices for controlled drug release in gastrointestinal tract. <b>2017</b> , 157, 9-20	39
510	Symptomatic Microscopic Colitis Atop Quiescent Inflammatory Bowel Disease: A Case Series. <b>2017</b> , 4, e124	3
509	Clinical characterization of inflammatory bowel disease with Raman spectroscopy. <b>2017</b> , 8, 524-535	31
508	Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review. <b>2017</b> , 12, 90-97	5
507	Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa?. <b>2017</b> , 9,	38
506	p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer. <b>2017</b> , 18,	23
505	Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. <b>2017</b> , 2017, 4535194	223
504	Host-microbial Cross-talk in Inflammatory Bowel Disease. <b>2017</b> , 17, 1-12	85
503	Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. <b>2017</b> , 9, 641-652	10
502	Second Korean guidelines for the management of ulcerative colitis. <b>2017</b> , 15, 7-37	40

501	[Second Korean Guideline for the Management of Ulcerative Colitis]. <b>2017</b> , 69, 1-28	16
500	Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland. <b>2017</b> , 12, 60-65	5
499	Diagnostic yield from colon biopsies in patients with inflammatory bowel disease and suspected cytomegalovirus infection: is it worth it?. <b>2017</b> , 30, 429-432	2
498	Approach to cytomegalovirus infections in patients with ulcerative colitis. <b>2017</b> , 32, 383-392	19
497	Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. <b>2018</b> , 24, 651-659	23
496	Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. <b>2018</b> , 130, 355-360	5
495	An Update on Surveillance in Ulcerative Colitis. <b>2018</b> , 20, 7	8
494	Cancer and Dysplasia Surveillance. <b>2018</b> , 71-100	
493	Colorectal Cancer in Inflammatory Bowel Disease. <b>2018</b> , 31, 168-178	104
492	Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation. <b>2018</b> , 47, 1428-1439	37
491	Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. <b>2018</b> , 97, 59-63	10
490	Frequency of Surveillance and Impact of Surveillance Colonoscopies in Patients With Ulcerative Colitis Who Developed Colorectal Cancer. <b>2018</b> , 17, e289-e292	6
489	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. <b>2018</b> , 110, 71-78	14
488	Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. <b>2018</b> , 11, 175-181	16
487	Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol. <b>2018</b> , 8, e019909	2
486	Evidence-based clinical practice guidelines for inflammatory bowel disease. <b>2018</b> , 53, 305-353	249
485	Immunogenicity of biologics in inflammatory bowel disease. <b>2018</b> , 11, 1756283X17750355	110
484	Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common. <b>2018</b> , 63, 713-722	7

483	Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. <b>2018</b> , 24, 286-295	10
482	Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF- $\alpha$ Antagonists. <b>2018</b> , 52, 571-579	8
481	Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. <b>2018</b> , 16, 1616-1621.e1	10
480	A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. <b>2018</b> , 36, 419-434	22
479	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. <b>2018</b> , 87, 1304-1309	16
478	Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study. <b>2018</b> , 47, 596-604	13
477	Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease. <b>2018</b> , 47, 143-144	0
476	Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 384-395	0.7 8
475	Factors Associated With Length of Stay in Veterans With Inflammatory Bowel Disease Hospitalized for an Acute Flare. <b>2017</b> , 24, 5-11	7
474	Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. <b>2018</b> , 24, 2272-2277	7
473	Systematic review: safety of mesalazine in ulcerative colitis. <b>2018</b> , 47, 1597-1609	49
472	Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. <b>2018</b> , 6, 61-64	9
471	Endocytoscopic classification can be predictive for relapse in ulcerative colitis. <b>2018</b> , 97, e0107	18
470	Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. <b>2018</b> , 19, 229-240	17
469	Food avoidance in patients with inflammatory bowel disease: What, when and who?. <b>2018</b> , 37, 884-889	25
468	Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease. <b>2018</b> , 17, e29-e37	25
467	Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis. <b>2018</b> , 67, 147-155	8
466	The application of molecular topology for ulcerative colitis drug discovery. <b>2018</b> , 13, 89-101	2



465	Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. <b>2018</b> , 16, 528-533		17
464	Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. <b>2018</b> , 104, 119-126		37
463	Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. <b>2018</b> , 30, 236-244		11
462	Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 58-71	0.7	27
461	Primary care management of ulcerative colitis. <b>2018</b> , 43, 11-19		3
460	Radioiodination and biological evaluation of mesalamine as a tracer for ulcerative colitis imaging. <b>2018</b> , 106, 393-400		10
459	Antitumor Necrosis Factor Agents in Ulcerative Colitis. <b>2018</b> , 13-32		
458	Pediatric Gastroenterologists' Approach to Venous Thromboembolism Prophylaxis in Pediatric Inflammatory Bowel Disease. <b>2018</b> , 66, 286-288		8
457	There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. <b>2018</b> , 52, 333-338		15
456	Inflammatory bowel disease: cost-driving factors and impact of cost sharing on outpatient resource utilization. <b>2018</b> , 9, 301-307		1
455	Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance. <b>2018</b> , 38, 220-230		7
454	UEG Week 2018 Poster Presentations. <b>2018</b> , 6, A135		14
453	Current Status of Clostridium Difficile Infection. <b>2018</b> , 71, 456-469		1
452	Recommender System for Diagnosis of Colon Diseases. <b>2018</b> ,		1
451	Fibrosis in Ulcerative Colitis. <b>2018</b> , 147-157		0
450	Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer. <b>2018</b> , 16, 3658-3664		6
449	Compliance with Guidelines on Thromboprophylaxis for Acutely Admitted Medical Patients. <b>2018</b> , 35, 1873-1883		1
448	Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1801-1809	0.7	37

447	Scientific evidence underlying the American College of Gastroenterology's clinical practice guidelines. <b>2018</b> , 13, e0204720	12
446	Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. <b>2018</b> , 24, 2431-2441	52
445	Ascorbyl Palmitate Hydrogel for Local, Intestinal Delivery of Macromolecules. <b>2018</b> , 10,	7
444	Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. <b>2018</b> , 1, 129-134	6
443	The Bisindole Alkaloid Caulerpin, from Seaweeds of the Genus , Attenuated Colon Damage in Murine Colitis Model. <b>2018</b> , 16,	24
442	Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. <b>2018</b> , 12, 2601-2609	19
441	Colorectal cancer resection rates in patients with inflammatory bowel disease: a population-based study. <b>2018</b> , 6, 263-269	7
440	Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. <b>2018</b> , 12, 1021-1029	15
439	Treatment of Inflammatory Bowel Disease in the Older Patient. <b>2018</b> , 24, 1155-1166	5
438	Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?. <b>2018</b> , 63, 2445-2450	8
437	Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. <b>2018</b> , 24, 2543-2549	6
436	The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. <b>2018</b> , 2018, 5480961	13
435	Promotes Repair of Colonic Microvascular Injury in Sprague-Dawley Rats with Experimental Colitis. <b>2018</b> , 2018, 4386571	3
434	Inflammatory Bowel Disease. <b>2018</b> , 230-233	
433	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. <b>2018</b> , 50, 1019-1029	12
432	Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. <b>2018</b> , 13, 61-68	3
431	The Probiotic, ID-JPL934, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice Through Inhibition of Proinflammatory Cytokines Expression. <b>2018</b> , 21, 858-865	14
430	[Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. <b>2018</b> , 71, 61-68	3

429	Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. <b>2018</b> , 22, 17-167	11
428	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. <b>2018</b> , 32-33, 17-25	7
427	Surgical Treatment of Inflammatory Bowel Diseases in the Elderly. <b>2018</b> , 191-206	4
426	Curcumin as a therapeutic agent for blocking NF- $\kappa$ B activation in ulcerative colitis. <b>2018</b> , 40, 476-482	37
425	Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis. <b>2018</b> , 53, 1031-1042	26
424	Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. <b>2018</b> , 12, 883-897	13
423	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. <b>2018</b> , 11, 215-226	71
422	Pharmacotherapy of ulcerative colitis - current status and emerging trends. <b>2018</b> , 29, 581-592	11
421	Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. <b>2018</b> , 40, 1509-1521.e5	12
420	Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. <b>2018</b> , 21, 869-877	1
419	Contemporary Medical Management of Acute Severe Ulcerative Colitis. <b>2019</b> , 25, 56-66	6
418	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <b>2018</b> , 12, 1158-1169	70
417	Tissue Sampling, Specimen Handling, and Laboratory Processing. <b>2019</b> , 51-68.e6	2
416	Dysplasia Surveillance in Inflammatory Bowel Disease. <b>2019</b> , 435-445.e3	
415	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <b>2019</b> , 58, 15-37	46
414	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <b>2019</b> , 71, 1285-1299	80
413	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <b>2019</b> , 71, 1599-1613	210
412	Anti-inflammatory effects of mulberry twig extracts on dextran sulfate sodium-induced colitis mouse model. <b>2019</b> , 52, 139	

411	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. <b>2019</b> , 85, 2244-2254	5
410	From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease. <b>2019</b> , 38, 247-262	
409	Ulcerative Colitis. <b>2019</b> , 94, 1357-1373	97
408	An approach to acute severe ulcerative colitis. <b>2019</b> , 13, 943-955	5
407	Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease. <b>2019</b> , 1,	7
406	Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. <b>2019</b> , 19, 179	5
405	Abdominal Emergencies in Inflammatory Bowel Disease. <b>2019</b> , 99, 1141-1150	15
404	Korean Traditional Medicine ( ) Ameliorates Colitis by Regulating Gut Microbiota. <b>2019</b> , 9,	8
403	Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. <b>2019</b> , 4, 115-122	3
402	Inflammatory bowel disease in patients undergoing renal biopsies. <b>2019</b> , 12, 645-651	6
401	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <b>2019</b> , 68, s1-s106	557
400	Gastrointestinal Tract Disorders in Older Age. <b>2019</b> , 2019, 6757524	70
399	Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. <b>2019</b> , 34, 1166-1174	10
398	Acupuncture in Inflammatory Bowel Disease. <b>2019</b> , 25, 1129-1139	25
397	Venous thromboembolism in colorectal surgery: Incidence, risk factors, and prophylaxis. <b>2019</b> , 42, 863-873	10
396	Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era. <b>2019</b> , 29, 531-548	5
395	Risk Factors for Venous Thromboembolism in Children and Young Adults With Inflammatory Bowel Disease. <b>2019</b> , 243, 173-179	10
394	Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. <b>2019</b> , 35, 1751-1759	8

393	New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. <b>2019</b> , 8, 212572	54
392	Saikosaponin A protects against dextran sulfate sodium-induced colitis in mice. <b>2019</b> , 72, 454-458	9
391	Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. <b>2019</b> , 90, 186-195.e1	43
390	Drug Toxicity: Personalising IBD Therapeutics □ The Use of Genetic Biomarkers to Reduce Drug Toxicity. <b>2019</b> , 257-269	0
389	Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation. <b>2019</b> , 64, 3256-3262	4
388	Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. <b>2019</b> , 23,	10
387	Ulcerative colitis - treatment with biologicals. <b>2019</b> , 65, 547-553	1
386	The mouth in inflammatory bowel disease and aspects of orofacial granulomatosis. <b>2019</b> , 80, 61-76	7
385	The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis. <b>2019</b> , 2019, 1287493	7
384	An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. <b>2019</b> , 22, 859-868	12
383	Cases report: severe colonic bleeding in ulcerative colitis is refractory to selective transcatheter arterial embolization. <b>2019</b> , 19, 55	1
382	Assessment of the procoagulant potential and associated risk factors in pregnant patients with inflammatory bowel diseases. <b>2019</b> , 65, 63-68	2
381	Histopathological diagnosis of ulcerative colitis-associated neoplasia. <b>2019</b> , 31 Suppl 1, 31-35	13
380	Evaluation of a Methylcellulose and Hyaluronic Acid Hydrogel as a Vehicle for Rectal Delivery of Biologics. <b>2019</b> , 11,	12
379	Anthropometric Assessment After Proctocolectomy Due to Ulcerative Colitis. <b>2019</b> , 33, 239-243	1
378	Ulcerative Colitis: Shifting Sands. <b>2019</b> , 19, 227-234	9
377	A comprehensive review and update on ulcerative colitis. <b>2019</b> , 65, 100851	103
376	The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism. <b>2019</b> , 12, 1178638819834526	4

375	Reply to Comment on "Inflammatory Bowel Diseases Were Associated With Risk of Sexual Dysfunction in Both Sexes: A Meta-analysis" by Li Y and Liu X. <b>2019</b> , 25, e78-e81	
374	Endoscopic detection and resection of dysplasia in inflammatory bowel disease-techniques with videos. <b>2019</b> , 34, 569-580	3
373	Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. <b>2019</b> , 7, 1565889	5
372	Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study. <b>2019</b> , 13, 1311-1317	65
371	Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. <b>2019</b> , 7, E568-E575	16
370	Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol. <b>2019</b> , 25, 1822-1827	16
369	Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <b>2019</b> , 13, 1105-1110	17
368	Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis. <b>2019</b> , 44, 409-414	1
367	Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. <b>2019</b> , 10, 212	53
366	Colorectal Cancer in Ulcerative Colitis: Surveillance. <b>2019</b> , 258-270	
365	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. <b>2019</b> , 13, 1217-1226	4
364	Efficacy and Safety of Abirilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. <b>2019</b> , 156, 946-957.e18	39
363	Systematic review with meta-analysis: Chromoendoscopy versus white light endoscopy in detection of dysplasia in patients with inflammatory bowel disease. <b>2019</b> , 20, 206-214	5
362	Acute Dermato-Lymphangio-Adenitis Following Administration of Infliximab for Crohn's Disease. <b>2019</b> , 6, e00075	0
361	IBD in the Elderly: Management Challenges and Therapeutic Considerations. <b>2019</b> , 21, 60	10
360	Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. <b>2019</b> , 9, 17751	4
359	Too Soon to Discard 5-ASAs?. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 534-535	0.7
358	Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A propensity matched retrospective cohort study. <b>2019</b> , 98, e16551	6

357	Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 483-489	16
356	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <b>2019</b> , 17, 139-147	78
355	Wheat gluten intake increases the severity of experimental colitis and bacterial translocation by weakening of the proteins of the junctional complex. <b>2019</b> , 121, 361-373	9
354	Standards of diagnostic colonoscopy for early-stage neoplasia: Recommendations by an Asian private group. <b>2019</b> , 31, 227-244	10
353	Ginsenoside Rb1 promotes intestinal epithelial wound healing through extracellular signal-regulated kinase and Rho signaling. <b>2019</b> , 34, 1193-1200	8
352	EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation. <b>2019</b> , 234, 11654-11661	22
351	A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 472-482	0.7 54
350	A Meta-analysis of Sexual Function in Patients With Inflammatory Bowel Disease: Examining a Small Piece of the Puzzle. <b>2019</b> , 25, 708-710	
349	Immunological Diseases of the Gastrointestinal Tract. <b>2019</b> , 1005-1019.e1	2
348	An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. <b>2019</b> , 25, 902-913	31
347	Management of Ulcerative Colitis in the Elderly. <b>2019</b> , 36, 13-27	3
346	Current Medical Therapies for Ulcerative Colitis. <b>2019</b> , 1-15	
345	Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. <b>2019</b> , 13, 182-188	11
344	Comparison of a novel predictor of venous thromboembolic complications in inflammatory bowel disease with current predictors. <b>2019</b> , 34, 870-879	6
343	Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. <b>2019</b> , 13, 172-181	17
342	Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. <b>2019</b> , 53, e1-e11	23
341	Inflammatory cells implicated in neoplasia development in idiopathic inflammatory bowel disease. <b>2019</b> , 343, 103720	
340	Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. <b>2019</b> , 20, 195-203	3

339	Feasibility of restorative proctocolectomy in patients with ulcerative colitis-associated lower rectal cancer: A retrospective study. <b>2019</b> , 42, 267-273	5
338	Endoscopic surveillance strategies for dysplasia in ulcerative colitis. <b>2020</b> , 11, 124-132	3
337	Risk factors for locally advanced cancer associated with ulcerative colitis: Results of a retrospective multicentric study in the era of biologics. <b>2020</b> , 52, 33-37	2
336	Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. <b>2020</b> , 26, 941-948	2
335	Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. <b>2020</b> , 3, 169-176	2
334	Venous Thrombosis in Pediatric Inflammatory Bowel Disease. <b>2020</b> , 216, 213-217	0
333	Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study. <b>2020</b> , 26, 291-300	10
332	Colitis, Ulcerative. <b>2020</b> , 552-574	
331	Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease. <b>2020</b> , 26, 1394-1400	13
330	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <b>2020</b> , 51, 271-280	27
329	Ulcerative Colitis: Current and Emerging Treatment Strategies. <b>2019</b> , 9,	19
328	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. <b>2020</b> , 158, 550-561	63
327	Effect of dietary probiotics on colon length in an inflammatory bowel disease-induced murine model: A meta-analysis. <b>2020</b> , 103, 1807-1819	11
326	Mesalamine in the Initial Therapy of Ulcerative Colitis. <b>2020</b> , 49, 689-704	2
325	Assessing Severity of Disease in Patients with Ulcerative Colitis. <b>2020</b> , 49, 671-688	10
324	Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey. <b>2020</b> , 1-9	2
323	The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. <b>2021</b> , 27, 1270-1276	0
322	A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis. <b>2020</b> , 144, 111628	4



321	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. <b>2020,</b>	5
320	A young woman who developed ascending colon cancer 2 years after the onset of ulcerative colitis. <b>2020, 13, 1189-1195</b>	1
319	Gallincin ameliorates colitis-associated inflammation and barrier function in mice based on network pharmacology prediction. <b>2020, 48, 300060520951023</b>	2
318	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. <b>2021, 15, 1130-1141</b>	6
317	Aqueous Leaf Extract of Improves Acute Acetic Acid-Induced Colitis in Rats by Reducing Inflammation and Oxidative Stress. <b>2021, 24, 697-708</b>	2
316	Defining the 'phenotype, pathogenesis and treatment of Crohn's disease' associated spondyloarthritis. <b>2020, 55, 667-678</b>	3
315	Chemical Characterization of Bioactive Components of Extract and Its Protective Effect on Dextran Sulfate Sodium-Induced Intestinal Bowel Disease in a Mouse Model. <b>2020, 23, 1109-1119</b>	3
314	Elderly-onset vs adult-onset ulcerative colitis: a different natural history?. <b>2020, 20, 147</b>	7
313	Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials. <b>2020, 21, 396</b>	3
312	The effect of 6-gingerol on inflammatory response and Th17/Treg balance in DSS-induced ulcerative colitis mice. <b>2020, 8, 442</b>	14
311	Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era. <b>2020, 13, 1756284820920779</b>	6
310	Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions. <b>2020, 13, 203-210</b>	11
309	Inflammatory bowel disease-associated neoplasia. <b>2020, 167-178</b>	
308	Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. <b>2020, 14, 1274-1281</b>	0
307	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. <b>2020, 20, 100271</b>	13
306	The Association of Mesalamine With Kidney Disease. <b>2020, 27, 72-76</b>	7
305	Emerging therapies for the treatment of ulcerative colitis. <b>2020, 1-9</b>	5
304	Reappraising Risk Factors for Inflammatory Bowel Disease-associated Neoplasia: Implications for Colonoscopic Surveillance in IBD. <b>2020, 14, 1172-1177</b>	8

303	Practical strategy for optimizing the timing of anti-tumor necrosis factor- $\alpha$ therapy in Crohn disease: A nationwide population-based study. <b>2020</b> , 99, e18925	1
302	A novel herbal formulation consisting of red ginseng extract and Nakai-attenuated dextran sulfate sodium-induced colitis in mice. <b>2020</b> , 44, 833-842	6
301	Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. <b>2020</b> , 13, 211-220	1
300	Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. <b>2020</b> , 34, 395-404	8
299	The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. <b>2020</b> , 10, 3658	7
298	Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. <b>2020</b> , 11, e00128	12
297	Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. <b>2020</b> , 158, 2139-2149. <del>614</del>	6
296	Use of an iPhone Application to Increase Adherence in Patients With Ulcerative Colitis in Remission: A Randomized Controlled Trial. <b>2020</b> , 26, e33-e34	6
295	Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. <b>2020</b> , 59, 1105-1109	5
294	Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model. <b>2020</b> , 317, 108943	14
293	Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer. <b>2020</b> , 34, 57-63	4
292	The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. <b>2020</b> , 20, 18	10
291	Anti-Inflammatory Effects of Huangqin Decoction on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1 $\alpha$ and NF- $\kappa$ B Pathways. <b>2019</b> , 10, 1552	22
290	Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. <b>2020</b> , 36, 771-779	7
289	Effects of Antibiotic Pretreatment of an Ulcerative Colitis-Derived Fecal Microbial Community on the Integration of Therapeutic Bacteria. <b>2020</b> , 5,	7
288	Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. <b>2020</b> , 4, 16	4
287	Real-world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan. <b>2021</b> , 8, 40-46	4
286	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. <b>2021</b> , 27, 816-825	8

285	Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. <b>2021</b> , 87, 1141-1149	
284	Chromoendoscopy with targeted biopsies is superior to white-light endoscopy for the long-term follow-up detection of dysplasia in ulcerative colitis patients: a multicenter randomized-controlled trial. <b>2021</b> , 9, 14-21	2
283	Systematic review on the management of ileoanal pouch-vaginal fistulas after restorative proctocolectomy in the treatment of ulcerative colitis. <b>2021</b> , 23, 34-51	0
282	Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data From 2006 to 2016. <b>2021</b> , 15, 358-366	11
281	Gastrointestinal diseases: Sex and gender evidence in liver lesions, gastroesophageal reflux, and inflammatory bowel disease. <b>2021</b> , 129-152	
280	Dental pulp stem cells overexpressing hepatocyte growth factor facilitate the repair of DSS-induced ulcerative colitis. <b>2021</b> , 12, 30	2
279	Pharmacology of Aging. <b>2021</b> , 249-277	
278	Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. <b>2021</b> , 13,	7
277	Endoscopic molecular imaging in inflammatory bowel disease. <b>2021</b> , 19, 33-44	3
276	Diagnostic and Treatment Methods for Ulcerative Colitis and Colitis-Associated Cancer. <b>2021</b> , 67-95	1
275	Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. <b>2021</b> , 34, 370-377	1
274	Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. <b>2021</b> , 21, 13	0
273	Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment. <b>2021</b> , 9, 3874-3884	5
272	Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy. <b>2021</b> , 62, 608-614	
271	Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. <b>2021</b> , 10, 229-240	4
270	Health and Financial Burdens Associated With Venous Thrombosis in Hospitalized Children With Inflammatory Bowel Disease. <b>2021</b> , 72, 748-751	2
269	Integrative transcriptomic and metabolomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis. <b>2021</b> , 13, 5087-5103	0
268	Association between Optic Neuritis and Inflammatory Bowel Disease: A Population-Based Study. <b>2021</b> , 10,	0

267	Venous Thromboembolism in Pediatric Inflammatory Bowel Disease: A Case-Control Study. <b>2021</b> , 72, 742-747	2
266	Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study. <b>2021</b> , 25, 2610-2618	1
265	Effect of <i>Cynara cardunculus</i> L. var. <i>altilis</i> (DC) in Inflammatory Bowel Disease. <b>2021</b> , 11, 1629	2
264	Valorization of Algerian Grape Pomace Seeds: Extraction of Bioactive Compounds, Prevention and Treatment of Experimental Inflammatory Bowel Diseases. <b>2021</b> , 12, 5401-5412	2
263	Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. <b>2021</b> , 15, 1481-1490	1
262	Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. <b>2021</b> , 21, 121	
261	Efficacy and safety of Shenling Atractylodes Powder in the treatment of ulcerative colitis: A protocol for systematic review and meta-analysis. <b>2021</b> , 100, e25355	
260	Text Mining-Based Drug Discovery in Osteoarthritis. <b>2021</b> , 2021, 6674744	2
259	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <b>2021</b> , 56, 489-526	40
258	Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics. <b>2021</b> , 26,	3
257	Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. <b>2021</b> , 113-123	1
256	The PI3K pathway as a therapeutic intervention point in inflammatory bowel disease. <b>2021</b> , 9, 804-818	2
255	Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. <b>2021</b> , 53, 691-696	2
254	Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. <b>2021</b> , 27, 3396-3412	1
253	Diseases of the Gastrointestinal Tract. <b>2021</b> , 553-577	
252	Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. <b>2021</b> ,	3
251	Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy. <b>2021</b> , 3,	0
250	Identification of an Anti-Integrin $\alpha 4 \beta 7$ Autoantibody in Patients With Ulcerative Colitis. <b>2021</b> , 160, 2383-2394.e2111	

249	Therapeutic effect of an anti-tuberculosis agent, isoniazid, and its nano-isoform in ulcerative colitis. <b>2021</b> , 96, 107577	3
248	Colorectal Strictures in Patients With Inflammatory Bowel Disease Do Not Independently Predict Colorectal Neoplasia. <b>2021</b> ,	2
247	Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center.	
246	Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF- $\kappa$ B Signaling Pathway and Gut Microbiota. <b>2021</b> , 12, 674416	5
245	Physical activity and quality of life of patients with inflammatory bowel disease. <b>2021</b> , 100, e26290	2
244	Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands. <b>2021</b> , 8,	1
243	The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. <b>2021</b> , 53, 965-971	3
242	Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. <b>2021</b> , 11,	1
241	Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. <b>2021</b> ,	0
240	Safety of transanal ileal pouch-anal anastomosis for ulcerative colitis: a retrospective observational cohort study. <b>2021</b> , 15, 31	0
239	Draft Genome Sequence of <i>Paraclostridium bifermentans</i> subsp. Strain PAGU 1678, Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis. <b>2021</b> , 10, e0078021	
238	Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. <b>2021</b> , 16, e0257599	
237	Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety. <b>2021</b> ,	2
236	Defecation Function After Laparo-Assisted Restorative Proctocolectomy with Ileal Pouch Anal Anastomosis for Ulcerative Colitis. <b>2021</b> ,	
235	The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. <b>2021</b> , 192, 114691	1
234	Digestive Tract Disease. <b>2021</b> , 511-552	
233	Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. <b>2021</b> , 34, 612-624	0
232	Abdominal Pain. <b>2021</b> ,	

231	The rectal mucosal but not fecal microbiota detects subclinical ulcerative colitis. <b>2021</b> , 13, 1-10	1
230	Anxiety in Children with Chronic Medical Illness. <b>2013</b> , 317-343	1
229	Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis. <b>2014</b> , 69-99	1
228	Ulcerative Proctitis and Anorectal Crohn's Disease. <b>2019</b> , 531-554	1
227	Concepts in Inflammatory Bowel Disease Management. <b>2019</b> , 1888-1918	1
226	Therapeutic applications of probiotics in ulcerative colitis: An updated review. <b>2020</b> , 13, 100194	16
225	Ultraperformance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics and Lipidomics Identify Biomarkers for Efficacy Evaluation of Mesalazine in a Dextran Sulfate Sodium-Induced Ulcerative Colitis Mouse Model. <b>2021</b> , 20, 1371-1381	8
224	Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. <b>2016</b> , 3, 8-16	6
223	Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. <b>2017</b> , 5, E974-E979	11
222	Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. <b>2021</b> , 27, 1593-1601	1
221	Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study. <b>2021</b> , 55, 702-708	8
220	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. <b>2018</b> , 47, 454-465	87
219	Venous and arterial disease in inflammatory bowel disease. <b>2013</b> , 28, 1095-1113	49
218	Remission endpoints in ulcerative colitis: A systematic review. <b>2017</b> , 5, 85	3
217	Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. <b>2016</b> , 11, e0158017	75
216	Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. <b>2016</b> , 11, e0160444	7
215	Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. <b>2016</b> , 11, e0165435	62
214	Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. <b>2017</b> , 12, e0175099	21

213	Clinical and Pathological Features of Ulcerative Colitis in Patients with and without Infection; An Observational Study. <b>2019</b> , 11, 17-23	3
212	Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. <b>2018</b> , 46, 445-463	27
211	Pharmacogenetics of thiopurines.. <b>2019</b> , 2, 256-270	3
210	Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. <b>2017</b> , 30, 192-196	7
209	Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. <b>2019</b> , 19, 959-974	6
208	Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. <b>2016</b> , 4, e13	48
207	Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. <b>2019</b> , 8, e1307	2
206	Current Status and Trends in Inflammatory Bowel Disease Surgery in Korea: Analysis of Data in a Nationwide Registry. <b>2018</b> , 34, 299-305	8
205	Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. <b>2018</b> , 6, 96-112	5
204	Current treatment of ulcerative colitis. <b>2011</b> , 17, 3204-12	72
203	Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. <b>2011</b> , 17, 3467-78	23
202	Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. <b>2013</b> , 19, 2979-84	13
201	Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. <b>2013</b> , 19, 6375-82	8
200	Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. <b>2013</b> , 19, 8659-70	23
199	Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. <b>2014</b> , 20, 3327-34	12
198	Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. <b>2014</b> , 20, 4980-6	29
197	Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. <b>2014</b> , 20, 509-17	20
196	Managing osteoporosis in ulcerative colitis: something new?. <b>2014</b> , 20, 14087-98	18

195	Hepatitis B vaccination in patients with inflammatory bowel disease. <b>2014</b> , 20, 15358-66	19
194	Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: a meta-analysis. <b>2014</b> , 20, 15899-909	15
193	Tools for primary care management of inflammatory bowel disease: do they exist?. <b>2015</b> , 21, 4457-65	17
192	Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. <b>2015</b> , 21, 8776-86	11
191	CTLA-4 and MDR1 polymorphisms increase the risk for ulcerative colitis: A meta-analysis. <b>2015</b> , 21, 10025-40	10
190	Histological healing after infliximab induction therapy in children with ulcerative colitis. <b>2015</b> , 21, 10654-61	9
189	Albumin as a prognostic marker for ulcerative colitis. <b>2017</b> , 23, 8008-8016	20
188	Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. <b>2019</b> , 25, 5862-5882	25
187	protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis. <b>2020</b> , 20, 10	9
186	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. <b>2020</b> , 35, 41-59	10
185	The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. <b>2020</b> , 27, 4	9
184	Early Outcome of Patient with Ulcerative Colitis who Received High Dose of Steroid and Underwent Two Staged Total Proctocolectomy. <b>2018</b> , 7, 11	4
183	Disparity in clinical care for patients with inflammatory bowel disease between specialists and non-specialists. <b>2013</b> , 03, 64-71	2
182	Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. <b>2015</b> , 7, 360-9	5
181	Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis: A systematic review and network meta-analysis. <b>2020</b> , 12, 159-171	3
180	Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations. <b>2017</b> , 9, 255-262	13
179	"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. <b>2014</b> , 5, 54-62	7
178	Minimally invasive surgery for inflammatory bowel disease: Review of current developments and future perspectives. <b>2016</b> , 7, 217-26	13



177	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. <b>2016</b> , 7, 387-96	6
176	Ethnic variations in ulcerative colitis: Experience of an international hospital in Thailand. <b>2016</b> , 7, 428-33	5
175	Combination therapy for inflammatory bowel disease. <b>2017</b> , 8, 103-113	21
174	Pharmacologic treatment for inflammatory bowel disease. <b>2015</b> , 58, 57	2
173	Guidelines for the Management of Ulcerative Colitis. <b>2012</b> , 10, 1	9
172	Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy. <b>2014</b> , 12, 12-9	23
171	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. <b>2018</b> , 16, 522-528	11
170	Efficacy and safety of abrilumab, an $\alpha 4 \beta 7$ integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. <b>2019</b> , 17, 375-386	10
169	Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. <b>2018</b> , 16, 69-74	7
168	Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. <b>2020</b> , 18, 355-378	7
167	Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI). <b>2021</b> , 19, 386-397	5
166	Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease. <b>2017</b> , 50, 437-445	4
165	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <b>2021</b> ,	2
164	Tofacitinib for a Child with Refractory Steroid-Dependent Ulcerative Colitis: A Case Report and Review of the Literature. <b>2021</b> , 22, e934460	0
163	A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. <b>2021</b> , 56, 1062-1079	1
162	Epidemiology and Screening of Colorectal Cancer. <b>2011</b> , 55-63	
161	Inflammatory bowel disease. <b>2011</b> , 86-92	
160	Diagnosis and Management of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. <b>2012</b> , 701-711	

- 159 Inflammatory Bowel Disease Associated Colorectal Neoplasia. **2012**, Suppl 8, 002
- 158 Molecular Pathology of Inflammatory Bowel Disease-Associated Neoplasia. **2013**, 173-178
- 157 A Primer on IBD: Phenotypes, Diagnosis, Treatment, and Clinical Challenges. **2013**, 3-21
- 156 Immunologic diseases of the gastrointestinal tract. **2013**, 896-909
- 155 Gastrointestinal Disease. **2013**, 169-184
- 154 Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis. **2014**, 439-456
- 153 Topical Mesalamine. **2014**, 101-110
- 152 Management of Steroid-Dependent and Steroid-Refractory Ulcerative Colitis. **2014**, 313-320
- 151 Step-Up Versus Top-Down Therapy in Ulcerative Colitis. **2014**, 457-467
- 150 Treatment of Ulcerative Proctitis. **2014**, 251-254
- 149 Cyclosporine for Ulcerative Colitis. **2014**, 153-166
- 148 Oral and Parenteral Corticosteroid Therapy in Ulcerative Colitis. **2014**, 111-119
- 147 Oral Mesalamine. **2014**, 55-68
- 146 Safety Considerations in the Medical Therapy of Ulcerative Colitis. **2014**, 297-311
- 145 Chemoprevention in Ulcerative Colitis. **2014**, 291-296
- 144 Ulcerative colitis. **2014**, 119-140
- 143 Medical Management of Toxic Megacolon. **2014**, 359-365
- 142 Principles of Medical Management of Ulcerative Colitis. **2014**, 31-44

141 Assessment of Disease Activity in Ulcerative Colitis. **2014**, 345-357

140 The Role of the Food and Drug Administration in Medical Therapy for Ulcerative Colitis. **2014**, 15-22

139 Endoscopic Surveillance for Neoplasia in IBD: Random Biopsy. **2015**, 237-250

138 Surveillance for Neoplasia in the Patient with an Ileal Pouch. **2015**, 259-265

137 Ileocolonoscopy in Inflammatory Bowel Diseases. **2015**, 1-29

136 Chapter 25. Gastrointestinal Diseases. **2015**,

135 [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. **2015**, 87, 34-38

4

134 Anti-MAdCAM antibody for induction of remission in ulcerative colitis.

133 Gastrointestinal Disease. 135-151

132 Ulcerative Colitis. 1378-1417

131 Colitis-Associated Cancer: Overview. **2016**, 1-19

130 Inflammatory Bowel Disease. **2016**, 45-63

129 Inflammatory Bowel Disease. **2016**, 183-201

128 Specifics and Pitfalls in Diagnosis of Inflammatory Bowel Diseases. **2016**, 1-9

127 Surgical Treatment for Ulcerative Colitis-Associated Cancer or Dysplasia. **2016**, 109-130

126 Celiac Disease and Inflammatory Bowel Disease. 983-989

125 Ulcerative Colitis, Colon. **2016**, 360-367

124 Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease. **2017**, 29-40

o

- 123 Which Ulcerative Colitis Patients Should Not Have Ileal Pouch-Anal Anastomosis. **2017**, 45-51
- 122 Chapter 25: Gastrointestinal Diseases. **2017**,
- 121 Dysplasia in Inflammatory Bowel Disease. **2018**, 141-154
- 120 A Common Complication After an Ileal Pouch-Anal Anastomosis With a Loop Ileostomy in Patients With Ulcerative Colitis: Small Bowel Obstruction. **2018**, 34, 57-58 1
- 119 Beclometasona oral. ¿Existen equivalentes más eficientes?. **2018**, 25, 387-388
- 118 Diagnostic accuracy of ultrasonography in comparison with colonoscopy for diagnosing of ulcerative colitis. **2018**, 9,
- 117 Therapeutic Management in Ulcerative Colitis. **2018**, 15, 61-72
- 116 What Is the Utility of ESR and CRP in the Evaluation of Acute IBD Presentations?. **2019**, 315-316
- 115 Management of Ulcerative Colitis in Patients with Rectal Cancer. **2019**, 273-278 1
- 114 Ulcerative Colitis. **2019**, 229-232
- 113 Primary Sclerosing Cholangitis Overlapping with IBD. **2019**, 191-204
- 112 Dietary Management. **2019**, 269-283 1
- 111 A Primer on IBD: Phenotypes, Diagnosis, Treatment, and Clinical Challenges. **2019**, 3-24 0
- 110 MicroRNAs and Inflammatory Bowel Disease. **2019**, 203-230 0
- 109 History of Ulcerative Colitis. **2019**, 1-16
- 108 Screening for Colon Cancer in Inflammatory Bowel Disease. **2019**, 17-31
- 107 Role of Endoscopic Management in Ulcerative Colitis Patients with Dysplasia. **2019**, 255-263
- 106 Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases. **2019**, 1-15 1

- 105 Temporal Gut Microbial Changes Predict Recurrent *Clostridium difficile* in Patients with and without Ulcerative Colitis.
- 104 Inpatient Management of Acute Severe Ulcerative Colitis. **2019**, 14, 766-773 5
- 103 [From Axial Spondyloarthritis to Osteoporosis - Spectrum of Skeletal Involvement in Inflammatory Bowel Diseases]. **2019**, 108, 799-806 1
- 102 Protective and Therapeutic Effect of Oleoresin of *Pistacia atlantica* in Acetic Acid-induced Colitis in Rat. **2019**, 4, 135-148
- 101 Preoperative Neutrophil-to-Lymphocyte Ratio Is Correlated with Severe Postoperative Complications After Emergency Surgery for Ulcerative Colitis. **2019**, 104, 514-521
- 100 Osteopathic Primary Care Treatment Options for Ulcerative Colitis. **2020**, 10-16
- 99 Microcarcinoid and Ulcerative Colitis: Case Report and Literature Review. **2020**, 12, e8803 2
- 98 Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis. **2021**, 25, 3208-3217 1
- 97 Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. **2022**, 29, 37-47 0
- 96 Perforated Toxic Megacolon: The Dreaded Complication in IBD. **2020**, 9, 70
- 95 Pharmacology of Aging. **2020**, 1-30
- 94 Glasgow prognostic score is a predictive index for postoperative infectious complications after total proctocolectomy in ulcerative colitis patients. **2021**, 113, 418-422
- 93 Gastrointestinal drugs. **2021**, 43, 415-429
- 92 Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives. **2021**, 22, 264
- 91 Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. **2021**, 55, 195-206 5
- 90 Navigating the complexity of ulcerative colitis: challenging case example. **2011**, 57, 568-72
- 89 Chromoendoscopy and Advanced Imaging Technologies for Surveillance of Patients with IBD. **2012**, 8, 796-802 4
- 88 Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis. **2014**, 10, 64-6 1

87	Commentary: vedolizumab: a new mechanism of action for the treatment of ulcerative colitis. <b>2014</b> , 10, 67-8	
86	Renal and Gastrointestinal Considerations in Joint Replacement Surgery. <b>2015</b> , 1, e46	3
85	Rectal cancer: a review. <b>2015</b> , 29, 171	14
84	Placental inflammation is not increased in inflammatory bowel disease. <b>2015</b> , 28, 457-63	2
83	Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. <b>2015</b> , 11, 1-16	3
82	Fertility and Contraception in Women With Inflammatory Bowel Disease. <b>2016</b> , 12, 101-9	4
81	Chromoendoscopy and Dysplasia Surveillance in Inflammatory Bowel Disease: Past, Present, and Future. <b>2015</b> , 11, 304-11	5
80	Fecal Microbiota Transplantation for Inflammatory Bowel Disease. <b>2016</b> , 12, 374-9	21
79	Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. <b>2014</b> , 10, 793-800	4
78	The Role of Chromoendoscopy in Evaluating Colorectal Dysplasia. <b>2017</b> , 13, 336-347	4
77	Improving IBD Care: A Personalized Approach to Management. <b>2018</b> , 14, 1-20	
76	Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease. <b>2018</b> , 11, 253-262	4
75	Prevalence of cytomegalovirus infection in patients with ulcerative colitis: a prospective cross-sectional study in Tehran, Iran. <b>2018</b> , 10, 342-347	
74	No Interval Cancers in Endoscopic Practice. <b>2019</b> , 45, 5-18	
73	Treatment De-Escalation in Patients With Inflammatory Bowel Disease. <b>2019</b> , 15, 335-341	1
72	A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis. <b>2020</b> , 16, 21-27	
71	Development of An HPLC Method for the Determination of Mesalazine in Human Plasma by Fluorimetric Derivatization and Application to A Prototype Pharmacokinetic Study. <b>2021</b> , 1	
70	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. <b>2021</b> ,	2

69	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. <b>2021</b> ,	5
68	Biomimetic MOF Nanoparticles Delivery of C-Dot Nanozyme and CRISPR/Cas9 System for Site-Specific Treatment of Ulcerative Colitis.. <b>2022</b> , 14, 6358-6369	2
67	SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes.. <b>2022</b> ,	0
66	Resveratrol Treatment Prevents Increase of Mast Cells in Both Murine OVA Enteritis and IL-10 Colitis.. <b>2022</b> , 23,	1
65	Host tp53 mutation induces gut dysbiosis eliciting inflammation through disturbed sialic acid metabolism.. <b>2022</b> , 10, 3	0
64	Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021.. <b>2022</b> , 28, 502-516	2
63	Synthesis, Radiolabeling, and Biological Evaluation of <sup>99m</sup> Tc-Tricarbonyl Mesalamine as a Potential Ulcerative Colitis Imaging Agent. <b>2021</b> , 63, 835-842	4
62	Inflammatory Bowel Disease: An Indication to Screen for Thrombophilia?. <b>2022</b> , 10,	
61	Secondary Indicators for an Evaluation and Guidance System for Quality of Care in Inflammatory Bowel Disease Centers: A Critical Review of the Inflammatory Bowel Disease Quality of Care Center.. <b>2022</b> ,	0
60	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.. <b>2022</b> ,	0
59	Measurement of Serum IgG Anti-Integrin $\alpha 4 \beta 7$ Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis.. <b>2022</b> , 11,	0
58	Chinese herbal medicines in the treatment of ulcerative colitis: a review.. <b>2022</b> , 17, 43	1
57	Mechanisms of Compound Sophora flavescens (Kushen) Decoction for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking Technology.. <b>2022</b> ,	
56	Toxisches Megakolon. <b>2022</b> , 1-7	
55	Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. <b>2021</b> ,	1
54	A lipidic mesophase with tunable release properties for the local delivery of macromolecules: the apoferritin nanocage, a case study.. <b>2022</b> ,	1
53	Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study.. <b>2022</b> , 9, 867293	0
52	The impact of delaying colonoscopies during the COVID-19 pandemic on colorectal cancer detection and prevention.. <b>2022</b> , 1	3

51	Cerebral Venous Sinus Thrombosis in Inflammatory Bowel Disease: A Review of Published Case Reports.. <b>2021</b> , 25,	
50	Treatment persistence and maintenance dose titration among ulcerative colitis on biologics: a pooled study of three United States claim databases.. <b>2022</b> , 1-25	1
49	Therapeutic strategies in Crohn's disease in an emergency surgical setting. <b>2022</b> , 28, 1902-1921	1
48	A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis. <b>2022</b> , 10,	0
47	Mass Cytometry and Single-Cell Transcriptome Analyses Reveal the Immune Cell Characteristics of Ulcerative Colitis. 9,	0
46	A new therapy against ulcerative colitis via the intestine and brain using the Si-based agent. <b>2022</b> , 12,	1
45	Further Validation of the Crohn's and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy. <b>2022</b> , 12, 436-448	1
44	Analysis of the Clinical Efficacy of Infliximab in the Treatment of Steroid-Refractory Ulcerative Colitis in Children. <b>2022</b> , In Press,	
43	Anti-integrin $\alpha 4 \beta 7$ antibody as a diagnostic marker for pediatric patients with ulcerative colitis. <b>2022</b> ,	0
42	Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods. <b>2022</b> , 12,	0
41	Extraction, Chemical Composition, and Protective Effect of Essential Oil from <i>Chimonanthus nitens</i> Oliv. Leaves on Dextran Sodium Sulfate-Induced Colitis in Mice. <b>2022</b> , 2022, 1-15	0
40	Is Hartmann's Pouch an Option in the Management of Acute Severe Ulcerative Colitis?. <b>2022</b> , 11, 3857	
39	The novel role of glucocorticoid-induced leucine zipper as a marker of mucosal healing in inflammatory bowel diseases. <b>2022</b> , 106353	1
38	High-volume colonic lavage is a safe and preferred colonoscopy preparation for patients with inflammatory bowel disease.	0
37	Stem Cell-Based Therapies for Inflammatory Bowel Disease. <b>2022</b> , 23, 8494	0
36	Renal and Urological Disorders Associated With Inflammatory Bowel Disease.	1
35	Hemin Ameliorates the Inflammatory Activity in the Inflammatory Bowel Disease: A Non-Clinical Study in Rodents. <b>2022</b> , 10, 2025	0
34	Construction, bioinformatics analysis, and validation of competitive endogenous RNA networks in ulcerative colitis. 13,	0



- 33 Perioperative Management of Ulcerative Colitis: A Systematic Review. Publish Ahead of Print,
- 32 Neuropeptide W Exhibits Preventive and Therapeutic Effects on Acetic Acid-Induced Colitis Via the Modulation of Cyclooxygenase Enzyme System. ○
- 31 In-Silico Study, Preparation and Biological Evaluation of 99MTC-Mesalamine Complex as Radiotracer for Diagnostics and Monitoring of Ulcerative Colitis in Mice. ○
- 30 Elucidating the Anti-Oxidant and Anti-Inflammatory Potentials of Triticum aestivum Against Ulcerative Colitis: an In Vivo and In Silico Study. **2022**, 100350 ○
- 29 Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. 2
- 28 Pathogenesis, diagnosis, dietary management, and prevention of gastrointestinal disorders in the paediatric population. **2022**, 48, ○
- 27 Cancer in Inflammatory Bowel Disease. **2022**, 51, 649-666 ○
- 26 A Molecular Biological Approach to the Diagnosis of Ulcerative Colitis-associated Cancer. **2022**, 75, 478-486 ○
- 25 Insights into current directions of protein and peptide-based hydrogel drug delivery systems for inflammation. ○
- 24 Treatment with Extracellular Vesicles from Giardia lamblia Alleviates Dextran Sulfate Sodium-Induced Colitis in C57BL/6 Mice. **2022**, 60, 309-315 ○
- 23 Hyaluronic Acid-Conjugated PLGA Nanoparticles Alleviate Ulcerative Colitis via CD44-Mediated Dual Targeting to Inflamed Colitis Tissue and Macrophages. **2022**, 14, 2118 ○
- 22 Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. **2022**, ○
- 21 Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report. **2022**, 101, e31757 ○
- 20 Single-cell and microarray chip analysis revealed the underlying pathogenesis of ulcerative colitis and validated model genes in diagnosis and drug response. ○
- 19 Hericium erinaceus mycelium -Derived Polysaccharide Alleviates Ulcerative Colitis and Modulates Gut Microbiota in Cynomolgus Monkeys. 2200450 ○
- 18 Anti-inflammatory and antioxidant activity of astragalus polysaccharide in ulcerative colitis: A systematic review and meta-analysis of animal studies. 13, ○
- 17 Inflammatory Bowel Disease in the Childbearing Adult and Newborn. **2023**, 24, 10-23 ○
- 16 Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. **2023**, Publish Ahead of Print, ○

- 15 Neuropeptide W Exhibits Preventive and Therapeutic Effects on Acetic Acid-Induced Colitis via Modulation of the Cyclooxygenase Enzyme System. ○
- 14 Surveillance for colorectal neoplasia in inflammatory bowel disease: When to stop. **2022**, Publish Ahead of Print, ○
- 13 Pharmacology Mechanism of Polygonum Bistorta in Treating Ulcerative Colitis Based on Network Pharmacology. **2022**, 2022, 1-18 ○
- 12 Current trends and future perspectives of probiotics on human health: an overview. **2023**, 81-122 ○
- 11 Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. 96-112 ○
- 10 Colitis-Associated Cancers. **2023**, 773-788 ○
- 9 The Role of Probiotics in Inducing and Maintaining Remission in Crohn's Disease and Ulcerative Colitis: A Systematic Review of the Literature. **2023**, 11, 494 ○
- 8 Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis. **2023**, 13, ○
- 7 Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors. **2023**, 46, 94-100 ○
- 6 Systematic review: Individual-level factors and social determinants of health impacting sleep health in individuals with inflammatory bowel disease. ○
- 5 Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments. **2023**, 15, 1031 ○
- 4 Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020. 1-11 ○
- 3 Identification of hub genes and immune infiltration in ulcerative colitis using bioinformatics. **2023**, 13, ○
- 2 Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy. **2023**, 15, 2389 ○
- 1 Network pharmacology-based identification of bioavailable anti-inflammatory agents from *Psoralea corylifolia* L. in an experimental colitis model. **2023**, 313, 116534 ○